10 results on '"Robert McGreevy"'
Search Results
2. Optical coherence tomography-guided coronary stent implantation compared to angiography: a multicentre randomised trial in PCI – design and rationale of ILUMIEN IV: OPTIMAL PCI
- Author
-
Robert McGreevy, Keyvan Karimi Galougahi, Akiko Maehara, Mitsuaki Matsumura, Jonathan Hill, Zhen Zhang, Takashi Akasaka, Gary S. Mintz, Nick E.J. West, Ori Ben-Yehuda, Francesco Prati, Richard Shlofmitz, Ziad A. Ali, Matthew J. Price, Hiram G. Bezerra, William Wijns, Gregg W. Stone, Giulio Guagliumi, Richard R. Rapoza, and Ulf Landmesser
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Lumen (anatomy) ,Stent ,030204 cardiovascular system & hematology ,medicine.disease ,law.invention ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,Randomized controlled trial ,law ,Intravascular ultrasound ,Coronary stent ,Conventional PCI ,medicine ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims Randomised trials have demonstrated improvement in clinical outcomes with intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) compared with angiography-guided PCI. The ILUMIEN III trial demonstrated non-inferiority of an optical coherence tomography (OCT)- versus IVUS-guided PCI strategy in achieving similar post-PCI lumen dimensions. ILUMIEN IV is a large-scale, multicentre, randomised trial designed to demonstrate the superiority of OCT- versus angiography-guided stent implantation in patients with high-risk clinical characteristics (diabetes) and/or complex angiographic lesions in achieving larger post-PCI lumen dimensions and improving clinical outcomes. Methods and results ILUMIEN IV is a prospective, single-blind clinical investigation that will randomise between 2,490 and 3,656 patients using an adaptive design to OCT-guided versus angiography-guided coronary stent implantation in a 1:1 ratio. The primary endpoints are: (1) post-PCI minimal stent area assessed by OCT in each randomised arm, and (2) target vessel failure, the composite of cardiac death, target vessel myocardial infarction, or ischaemia-driven target vessel revascularisation. Clinical follow-up will continue for up to two years. The trial is currently enrolling, and the principal results are expected in 2022. Conclusions The large-scale ILUMIEN IV randomised controlled trial will evaluate the effectiveness of OCT-guided versus angiography-guided PCI in improving post-PCI lumen dimensions and clinical outcomes in patients with diabetes and/or with complex coronary lesions. Trial registration NCT03507777.
- Published
- 2021
- Full Text
- View/download PDF
3. Late‐term safety and effectiveness of everolimus‐eluting stents in chronic total coronary occlusion revascularization: Final 4‐year results from the evaluation of the XIENCE coronary stent, Per formance, and T echnique in C hronic T otal O cclusions (EXPERT CTO) multicenter trial
- Author
-
Jin Wang, J. Aaron Grantham, Pradyumna E. Tummala, Robert McGreevy, Jeffrey J. Popma, David E. Kandzari, Weiying Zhao, Nicholas Lembo, Annapoorna Kini, Charles Orr, Dimitri Karmpaliotis, William J. Nicholson, William Lombardi, and Jeffrey W. Moses
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Stent ,General Medicine ,030204 cardiovascular system & hematology ,Revascularization ,03 medical and health sciences ,0302 clinical medicine ,Coronary occlusion ,Internal medicine ,Multicenter trial ,Conventional PCI ,Coronary stent ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Mace - Abstract
Background Limited study has detailed the late-term safety and efficacy of chronic total coronary occlusion (CTO) revascularization among multiple centers applying modern techniques and with newer-generation drug-eluting stents. Methods Among 20 centers, 222 patients enrolled in the XIENCE coronary stent, performance, and technique (EXPERT) CTO trial underwent CTO percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES). Through planned 4-year follow-up, the primary composite endpoint of major adverse cardiac events (MACE; death, myocardial infarction [MI] and target lesion revascularization) and rates of individual component endpoints and stent thrombosis were determined. Results Demographic, lesion, and procedural characteristics included prior bypass surgery, 9.9%; diabetes, 40.1%; lesion length, 36.1 ± 18.5 mm; and stent length, 51.7 ± 27.2 mm. By 4 years, MACE rates were 31.6 and 22.4% by the pre-specified ARC and per-protocol definitions, respectively. Clinically-indicated target lesion revascularization at 4 years was 11.3%. In landmark analyses of events beyond the first year of revascularization, the annualized rates of target vessel-related MI and clinically-indicated target lesion revascularization were 0.53 and 1.3%, respectively. Through 4 years, the cumulative definite/probable stent thrombosis rate was 1.7% with no events occurring beyond the initial year of index revascularization. Conclusions In a multicenter registration trial representing contemporary technique and EES, these results demonstrate sustained long-term safety and effectiveness of EES in CTO percutaneous revascularization and can be used to inform shared decision making with patients being considered for CTO PCI relative to late safety and vessel patency.
- Published
- 2019
- Full Text
- View/download PDF
4. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds
- Author
-
David G. Rizik, Robert McGreevy, Christopher Metzger, Jeffrey J. Popma, Steven O. Marx, Stephen G. Ellis, Ronald P. Caputo, Charles A. Simonton, Marc Litt, Dean J. Kereiakes, Ameer Kabour, Paul S. Teirstein, Absorb Iii Investigators, Gregg W. Stone, Annapoorna Kini, and Zhen Zhang
- Subjects
Target lesion ,medicine.medical_specialty ,Everolimus ,business.industry ,medicine.medical_treatment ,Stent ,030204 cardiovascular system & hematology ,medicine.disease ,Thrombosis ,law.invention ,Surgery ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Medicine ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Adverse effect ,medicine.drug - Abstract
Background The Absorb everolimus-eluting poly-L-lactic acid–based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES). Objectives This study sought to assess clinical outcomes through 3 years following BVS implantation. Methods Clinical outcomes from the ABSORB III trial were analyzed by randomized treatment assignment cumulative through 3 years, and between 1 and 3 years. Results The primary composite endpoint of target lesion failure through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (p = 0.06), and between 1 and 3 years in 7.0% versus 6.0% of patients, respectively (p = 0.39). TVMI through 3 years was increased with BVS (8.6% vs. 5.9%; p = 0.03), as was device thrombosis (2.3% vs. 0.7%; p = 0.01). In BVS-assigned patients, treatment of very small vessels (those with quantitatively determined reference vessel diameter Conclusions In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906)
- Published
- 2017
- Full Text
- View/download PDF
5. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I)
- Author
-
Geert Lauwers, Richard Rapoza, Antoine Sauguet, Marc Bosiers, Wouter Lansink, Robert McGreevy, Dierk Scheinert, Florian Wolf, Andrej Schmidt, Thomas Zeller, Frank Vermassen, Jeffrey J. Popma, Lewis B. Schwartz, Michael R. Jaff, Johannes Lammer, and Koen Deloose
- Subjects
medicine.medical_specialty ,Groin ,business.industry ,medicine.medical_treatment ,External iliac artery ,030204 cardiovascular system & hematology ,medicine.disease ,Surgery ,Coronary arteries ,03 medical and health sciences ,Dissection ,0302 clinical medicine ,Hematoma ,medicine.anatomical_structure ,Amputation ,Restenosis ,medicine.artery ,medicine ,030212 general & internal medicine ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Claudication ,business - Abstract
Objectives This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold (BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) and superficial femoral artery (SFA). Background Drug-eluting BVS has shown promise in coronary arteries. Methods The ESPRIT BVS system is a device-drug combination consisting of an everolimus-eluting poly-l-lactide scaffold. Safety and performance were evaluated in 35 subjects with symptomatic claudication. Results Lesions were located in the SFA (88.6%) and EIA (11.4%). Mean lesion length was 35.7 ± 16.0 mm. The study device was successfully deployed in 100% of cases, without recoil. Procedure-related minor complications were observed in 3 patients (groin hematoma, dissection). Within 2 years there was 1 unrelated death, but no patients in this cohort had an amputation. At 1 and 2 years, the binary restenosis rates were 12.1% and 16.1%, respectively, and target lesion revascularization was performed in 3 of 34 patients (8.8%) and 4 of 32 patients (11.8%), respectively. The ankle brachial index 0.75 ± 0.14 improved from pre-procedure to 0.96 ± 0.16 at 2 years’ follow-up. At 2 years, 71.0% of the patients were Rutherford-Becker 0, and 93.5% achieved a maximum walking distance of 1,500 feet. Conclusions The safety of the ESPRIT BVS was demonstrated with no procedure or device-related deaths or amputations within 2 years. The low occurrence of revascularizations was consistent with duplex-ultrasonography showing sustained patency at 2-years. (A Clinical Evaluation of the Abbott Vascular ESPRIT BVS [Bioresorbable Vascular Scaffold] System [ESPRIT I]; NCT01468974)
- Published
- 2016
- Full Text
- View/download PDF
6. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
- Author
-
Stephen G, Ellis, Dean J, Kereiakes, D Christopher, Metzger, Ronald P, Caputo, David G, Rizik, Paul S, Teirstein, Marc R, Litt, Annapoorna, Kini, Ameer, Kabour, Steven O, Marx, Jeffrey J, Popma, Robert, McGreevy, Zhen, Zhang, Charles, Simonton, Gregg W, Stone, and L, Deenan
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Coronary Artery Disease ,Kaplan-Meier Estimate ,Coronary Angiography ,Prosthesis Design ,Revascularization ,Angina Pectoris ,law.invention ,Coronary Restenosis ,Coronary artery disease ,Randomized controlled trial ,law ,Internal medicine ,Absorbable Implants ,medicine ,Clinical endpoint ,Humans ,Everolimus ,Myocardial infarction ,Aged ,Unstable angina ,business.industry ,Stent ,Drug-Eluting Stents ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Metals ,Cardiology ,Female ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
BACKGROUND In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascular scaffolds have been developed to attempt to improve longterm outcomes. METHODS In this large, multicenter, randomized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to receive an everolimus-eluting bioresorbable vascular (Absorb) scaffold (1322 patients) or an everolimus-eluting cobalt–chromium (Xience) stent (686 patients). The primary end point, which was tested for both noninferiority (margin, 4.5 percentage points for the risk difference) and superiority, was target-lesion failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization) at 1 year. RESULTS Target-lesion failure at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (difference, 1.7 percentage points; 95% confidence interval, −0.5 to 3.9; P = 0.007 for noninferiority and P = 0.16 for superiority). There was no significant difference between the Absorb group and the Xience group in rates of cardiac death (0.6% and 0.1%, respectively; P = 0.29), targetvessel myocardial infarction (6.0% and 4.6%, respectively; P = 0.18), or ischemiadriven target-lesion revascularization (3.0% and 2.5%, respectively; P = 0.50). Device thrombosis within 1 year occurred in 1.5% of patients in the Absorb group and in 0.7% of patients in the Xience group (P = 0.13). CONCLUSIONS In this large-scale, randomized trial, treatment of noncomplex obstructive coronary artery disease with an everolimus-eluting bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt–chromium stent, was within the prespecified margin for noninferiority with respect to target-lesion failure at 1 year. (Funded by Abbott Vascular; ABSORB III ClinicalTrials.gov number, NCT01751906.)
- Published
- 2015
- Full Text
- View/download PDF
7. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
- Author
-
Robert McGreevy, John A. Ormiston, Evelyn Regar, Yoshinobu Onuma, Mark Webster, Leif Thuesen, Susan Veldhof, Patrick W. Serruys, Dariusz Dudek, Hector M. Garcia-Garcia, and Cardiology
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Coronary Disease ,Coronary Restenosis ,Angioplasty ,Absorbable Implants ,Coronary stent ,Intravascular ultrasound ,medicine ,Humans ,Angioplasty, Transluminal, Percutaneous Coronary ,Everolimus ,Prospective Studies ,cardiovascular diseases ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,Ultrasonography ,Antibacterial agent ,Sirolimus ,Neointimal hyperplasia ,medicine.diagnostic_test ,business.industry ,Stent ,Drug-Eluting Stents ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Drug-eluting stent ,Female ,Radiology ,Safety ,business ,Immunosuppressive Agents - Abstract
Udgivelsesdato: 2008-Mar-15 BACKGROUND: A fully bioabsorbable drug-eluting coronary stent that scaffolds the vessel wall when needed and then disappears once the acute recoil and constrictive remodelling processes have subsided has theoretical advantages. The bioasorbable everolimus-eluting stent (BVS) has a backbone of poly-L-lactic acid that provides the support and a coating of poly-D,L-lactic acid that contains and controls the release of the antiproliferative agent everolimus. We assessed the feasibility and safety of this BVS stent. METHODS: In this prospective, open-label study we enrolled 30 patients who had either stable, unstable, or silent ischaemia and a single de-novo lesion that was suitable for treatment with a single 3.0 x 12 mm or 3.0 x 18 mm stent. Patients were enrolled from four academic hospitals in Auckland, Rotterdam, Krakow, and Skejby. The composite endpoint was cardiac death, myocardial infarction, and ischaemia-driven target lesion revascularisation. Angiographic endpoints were available for 26 patients and intravascular-ultrasound endpoints for 24 patients. Clinical endpoints were assessed in all 30 patients at 6 and 12 months. In a subset of 13 patients, optical coherence tomography was undertaken at baseline and follow-up. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00300131. FINDINGS: Procedural success was 100% (30/30 patients), and device success 94% (29/31 attempts at implantation of the stent). At 1 year, the rate of major adverse cardiac events was 3.3%, with only one patient having a non-Q wave myocardial infarction and no target lesion revascularisations. No late stent thromboses were recorded. At 6-month follow-up, the angiographic in-stent late loss was 0.44 (0.35) mm and was mainly due to a mild reduction of the stent area (-11.8%) as measured by intravascular ultrasound. The neointimal area was small (0.30 [SD 0.44] mm2), with a minimal area obstruction of 5.5%. INTERPRETATION: This study shows the feasibility of implantation of the bioabsorbable everolimus-eluting stent, with an acceptable in-stent late loss, minimal intrastent neointimal hyperplasia, and a low stent area obstruction. FUNDING: Abbott Vascular.
- Published
- 2008
- Full Text
- View/download PDF
8. TCT-438 Outcomes After Bailout Stenting with Absorb BVS or XIENCE: Meta-analysis of Randomized Trials
- Author
-
Stephen G. Ellis, Dean J. Kereiakes, Patrick W. Serruys, Robert McGreevy, Takeshi Kimura, Gregg W. Stone, Runlin Gao, Jennifer Jones, Xiaolu Su, Wai-Fung Cheong, Rony Lahoud, and Yoshinobu Onuma
- Subjects
medicine.medical_specialty ,Randomized controlled trial ,business.industry ,law ,Meta-analysis ,Medicine ,equipment and supplies ,Cardiology and Cardiovascular Medicine ,business ,Bioresorbable scaffold ,Surgery ,law.invention ,Bailout - Abstract
The Absorb bioresorbable scaffold (BVS) provides comparable 12-month clinical outcomes to Xience everolimus-eluting stents in appropriately sized vessels. Differences in device structure (strut thickness and width) and resorption might impact outcomes in the setting of bailout (unplanned) device
- Published
- 2016
- Full Text
- View/download PDF
9. TCT-57 Impact of Lesion Length on 1-year Outcomes of Absorb Bioresorbable Vascular Scaffolds
- Author
-
Rony Lahoud, Robert McGreevy, Wai-Fung Cheong, Jennifer Jones, Stephen G. Ellis, Zhengyang Zhang, Takeshi Kimura, Runlin Gao, Yoshinobu Onuma, and Dean J. Kereiakes
- Subjects
Lesion ,medicine.medical_specialty ,business.industry ,medicine ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Surgery - Published
- 2016
- Full Text
- View/download PDF
10. Scientific Review: New Opportunities for Data Analysis Software: An International Collaboration
- Author
-
Ian Anderson, Robert McGreevy, Steve Miller, Al Geist, and Toshiya Otoma
- Subjects
Engineering ,Nuclear and High Energy Physics ,business.industry ,Scientific discovery ,Oak Ridge National Laboratory ,Atomic and Molecular Physics, and Optics ,Data visualization ,Systems engineering ,Analysis software ,Spallation ,Instrumentation (computer programming) ,business ,Spallation Neutron Source ,Pace - Abstract
On three continents major new neutron scattering facilities are under construction that will provide unprecedented opportunities for scientific discovery. The Spallation Neutron Source (SNS) under construction at Oak Ridge National Laboratory (ORNL) will become operational in 2006, the Japanese Spallation Source is planned for completion in 2007, and the second target station at ISIS is due to come on-line in 2008. All three will be equipped with state-of-the-art instrumentation, large detector arrays and, with the associated increases in flux, will deliver orders of magnitude increases in data volume. Current data visualization and analysis software will be seriously challenged to keep pace with these changes.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.